Based on our findings, sintilimab plus anlotinib has promise as a chemotherapy‐free treatment regimen for patients with NSCLC harboring uncommon EGFR mutations after disease progression on standard of care treatment. This evidence concerns the gene EGFR and non-small cell lung carcinoma.